Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.71 |
| ▸ | RXRA | P19793 | 5/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21792125 | 0.83 | NOTUM (1.00) | NOTUMRXRAGRIN1GRIN2BNPC1 | |
| SCHEMBL21792038 | 0.81 | NOTUM (1.00) | NOTUMRXRAGRIN1GRIN2BCA12 | |
| SCHEMBL21792303 | 0.80 | NOTUM (0.64) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL21776821 | 0.77 | NOTUM (0.75) | NOTUMRXRAGRIN1GRIN2BNPC1 | |
| SCHEMBL21777017 | 0.73 | NOTUM (1.00) | NOTUMNPC1RAB9ACA12CA1 | |
| SCHEMBL26085015 | 0.73 | NOTUM (0.64) | NOTUMRXRAGRIN1GRIN2BNPC1 | |
| SCHEMBL15777276 | 0.70 | CNR2 (0.61) | — | |
| SCHEMBL15968661 | 0.69 | CNR2 (0.60) | — | |
| SCHEMBL22816089 | 0.69 | FFAR4 (0.44) | — | |
| SCHEMBL14788707 | 0.68 | CA1 (0.67) | NOTUMCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885RXRA 2925/4885GRIN1 642/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885RXRA 1952/4885GRIN1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.